Market Cap | 504.98M | P/E | - | EPS this Y | 45.30% | Ern Qtrly Grth | - |
Income | -198.64M | Forward P/E | -2.34 | EPS next Y | 47.50% | 50D Avg Chg | 11.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -6.00% |
Dividend | N/A | Price/Book | 1.22 | EPS next 5Y | - | 52W High Chg | -94.00% |
Recommedations | 2.00 | Quick Ratio | 4.01 | Shares Outstanding | 119.22M | 52W Low Chg | 93.00% |
Insider Own | 18.21% | ROA | -42.42% | Shares Float | 49.62M | Beta | 0.63 |
Inst Own | 63.93% | ROE | -74.48% | Shares Shorted/Prior | 4.25M/1.64M | Price | 4.64 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 660,960 | Target Price | 9.38 |
Oper. Margin | - | Earnings Date | - | Volume | 534,999 | Change | 0.87% |
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. It developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. The company's pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. Invivyd, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Guggenheim | Buy | Apr 5, 24 |
Morgan Stanley | Overweight | Mar 26, 24 |
HC Wainwright & Co. | Buy | Mar 25, 24 |
HC Wainwright & Co. | Buy | Jan 18, 24 |
Morgan Stanley | Equal-Weight | Dec 19, 23 |
HC Wainwright & Co. | Buy | Aug 14, 23 |
HC Wainwright & Co. | Buy | Jul 18, 23 |
HC Wainwright & Co. | Buy | Jun 23, 23 |
HC Wainwright & Co. | Buy | May 15, 23 |